Cooper Companies (The) (COO)

Nasdaq Health Care Health Care Supplies S&P 500
$62.36
-1.15 (-1.81%)
Close of Nov 06, 2026 · end-of-day data

COO 8-K filings in 2024

Every material Form 8-K Cooper Companies (The) filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.

Briefs in 2024216 on record in all
Latest filing in 2024Dec 05, 2024earnings
High impact (4-5)1of 2 briefs
TonePositive2
Dec 5, 4:21 PM ET

Cooper Companies Q4 revenue up 10% to $1,018.4 million; FY2025 EPS guidance $3.92-$4.02

Positive earnings Written later 2.02

Cooper Companies reported fiscal fourth-quarter 2024 revenue of $1,018.4 million, up 10%, and GAAP diluted EPS of $0.58, up 38%, with fiscal 2024 revenue of $3.9 billion and GAAP diluted EPS of $1.96. The company also issued its first fiscal 2025 financial guidance, projecting non-GAAP diluted EPS of $3.92 to $4.02 against fiscal 2024 non-GAAP EPS of $3.69.

  • Q4 2024 revenue $1,018.4 million, up 10% (up 7% organically); CooperVision $676.4 million, CooperSurgical $342.0 million
  • Q4 2024 GAAP diluted EPS $0.58, up 38%; non-GAAP diluted EPS $1.04, up 19%
  • Fiscal 2024 revenue $3,895.4 million, up 8%; GAAP diluted EPS $1.96; non-GAAP diluted EPS $3.69, up 15%
  • Fiscal 2025 guidance: total revenue $4,080 to $4,158 million; non-GAAP diluted EPS $3.92 to $4.02
Read the filing on SEC.gov ↗
Aug 28, 4:17 PM ET

CooperCompanies Q3 revenue rises 8% to $1,002.8 million; raises FY2024 guidance

Positive earnings Written later 2.02

CooperCompanies reported fiscal third-quarter 2024 results for the quarter ended July 31, 2024, with revenue up 8% year over year and GAAP diluted EPS up 22%. The company also raised its fiscal 2024 financial guidance, including non-GAAP diluted EPS of $3.64 to $3.67, which gives shareholders a higher outlook for the year.

  • Quarterly revenue of $1,002.8 million, up 8% year over year; CooperVision rose 7% to $675.6 million and CooperSurgical rose 9% to $327.2 million.
  • GAAP diluted EPS of $0.52, up $0.09 or 22%; non-GAAP diluted EPS of $0.96, up 14%.
  • Fiscal 2024 guidance raised: total revenue of $3,892 to $3,913 million and non-GAAP diluted EPS of $3.64 to $3.67.
  • GAAP operating margin of 19% versus 16% a year earlier; free cash flow of $118.5 million.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cooper Companies (The) filing is on SEC EDGAR ↗. 8-K briefs of other companies →